Cytomegalovirus (CMV) is still a major pathogen in liver transplantation (LTX). The clinical
efficacy of prophylactic high‐dose acyclovir therapy (800 mg qid) was assessed for the …

We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence
and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid …

The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to
prevent infection and disease in solid-organ transplant patients has not been evaluated by …

BACKGROUND: Cytomegalovirus (CMV) infection and related disease is a feared
complication after liver transplantation. Antiviral prophylaxis is recommended in clinical …

Cytomegalovirus (CMV) is an important cause of morbidity and mortality in liver transplant
recipients and several different strategies of CMV chemoprophylaxis are in practice. A cost …

Prophylaxis reduces cytomegalovirus (CMV) disease, but is associated with increased costs
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …

Background The VIPP study compared valganciclovir prophylaxis with preemptive treatment
regarding efficacy, safety, and long-term graft outcome in cytomegalovirus (CMV)-positive …

Background. Cytomegalovirus (CMV) D+/R− solid-organ transplant (SOT) recipients carry
increased risk of developing CMV disease; however, other risk factors in these patients have …

To the Editor—Legendre et al.[1] address an important and topical issue—namely, late-
onset cytomegalovirus (CMV) disease in transplant recipients who receive antiviral …

The widespread use of antiviral prophylaxis or preemptive therapy among orthotopic liver
transplantation (OLT) recipients has reduced the occurrence of early cytomegalovirus (CMV) …